Merck & Company Inc (MRK)vsXencor Inc (XNCR)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
XNCR
Xencor Inc
$38.13
-4.60%
HEALTHCARE · Cap: $3.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 33506% more annual revenue ($67.38B vs $200.49M). MRK leads profitability with a 3.6% profit margin vs -58.8%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
XNCR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Margin of Safety
+82.8%
Fair Value
$71.11
Current Price
$38.13
$32.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Revenue surging 454.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
ROE of -33.4% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : XNCR
The strongest argument for XNCR centers on Revenue Growth, Debt/Equity. Revenue growth of 454.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : XNCR
The primary concerns for XNCR are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while XNCR is a hypergrowth play — different risk/reward profiles.
XNCR carries more volatility with a beta of 0.77 — expect wider price swings.
XNCR is growing revenue faster at 454.9% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 30/100). XNCR offers better value entry with a 82.8% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Xencor Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?